SILtuximab in Viral ARds (SILVAR) Study

Summary

This study will evaluate the efficacy and safety of siltuximab compared with normal saline in combination with standard of care (SOC) in selected hospitalized patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection associated with acute respiratory distress syndrome (ARDS) and elevated C-reactive protein (CRP) levels.

Timeline

Start

2020-11-13

Primary completion

2021-04-01

Completion

2021-04-01

Drugs

Indications